Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in Sweden

Srivastava, T., Prabhu, V.S., Li, H. et al. (7 more authors) (2018) Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in Sweden. European Urology Oncology. ISSN 2588-9311

Abstract

Metadata

Authors/Creators:
  • Srivastava, T.
  • Prabhu, V.S.
  • Li, H.
  • Xu, R.
  • Zarabi, N.
  • Zhong, Y.
  • Pellisier, J.M.
  • Perini, R.F.
  • de Wit, R.
  • Mamtani, R.
Copyright, Publisher and Additional Information: © 2018 Merck Sharp & Dohme Corp and The Authors. Published Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Keywords: Bladder cancer; Cost-effectiveness; Immunotherapy; Pembrolizumab; Urothelial carcinoma
Dates:
  • Accepted: 25 September 2018
  • Published (online): 22 November 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Depositing User: Symplectic Sheffield
Date Deposited: 15 Mar 2019 11:47
Last Modified: 15 Mar 2019 11:47
Status: Published online
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.euo.2018.09.012

Share / Export

Statistics